NovaBridge Biosciences (NBP) Income from Continuing Operations (2019 - 2025)
NovaBridge Biosciences (NBP) posted quarterly Income from Continuing Operations of 72858000.0 for Q4 2025, down 2655.6% year-over-year from 2850918.34 in Q4 2024, and down 967.05% quarter-over-quarter from 6828000.0 in Q3 2025.
Powered by 
Analysis
NovaBridge Biosciences (NBP) Income from Continuing Operations (2019 - 2025) Analysis & Trends
NovaBridge Biosciences (NBP) has reported Income from Continuing Operations for 5 consecutive years, with 72858000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Income from Continuing Operations fell 2655.6% year-over-year to 72858000.0; the TTM figure through Dec 2025 stood at 88340000.0 (down 112.89% YoY), while the FY2025 annual figure was 88340000.0, down 112.89% from the prior year.
- Income from Continuing Operations retreated to 72858000.0 in Q4 2025 per NBP's latest filing, from 6828000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 2644000.0 in Q4 2024 and bottomed at 72858000.0 in Q4 2025.
- Historically, Income from Continuing Operations has averaged 18411363.64 across 3 years, with a median of 8942000.0 in 2024.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations surged 92.84% — and 2025, when it plunged 2655.6%.
- NovaBridge Biosciences' Income from Continuing Operations stood at 36910000.0 in 2023, then soared by 92.84% to 2644000.0 in 2024, then slumped by 2655.6% to 72858000.0 in 2025.
- Business Quant data shows NBP's Income from Continuing Operations at 72858000.0 in Q4 2025, 6828000.0 in Q3 2025, and 5504000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -13.27 Mn |
| 10 | NovaBridge Biosciences | 199.88 Mn | 199.88 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -88.34 Mn |
| Sep 30, 2025 | 8.65 Mn |
| Jun 30, 2025 | -5.50 Mn |
| Mar 31, 2025 | -3.15 Mn |
| Dec 31, 2024 | -49.70 Mn |
| Sep 30, 2024 | -20.49 Mn |
| Jun 30, 2024 | -8.94 Mn |
| Mar 31, 2024 | -9.42 Mn |
| Dec 31, 2023 | -36.91 Mn |
| Sep 30, 2023 | -8.22 Mn |
| Jun 30, 2023 | -27.56 Mn |
| Dec 31, 2020 | 160.85 Mn |
| Sep 30, 2020 | 1.77 Mn |
| Dec 31, 2019 | -49.46 Mn |
| Sep 30, 2019 | -35.10 Mn |